DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it expects to report revenue of approximately $2.4 million and $9.5 million for the fourth quarter and full year of 2009, respectively. These amounts represent increases of over 20% for each of the respective periods over the same periods in the prior year. Increased sales volume of our base gamma detection systems accounted for the increase in the fourth quarter and combined with revenue from new product introductions to account for the year-on-year increase.
